About Vernalis Therapeutics

Headquartered in Berwyn PA, Vernalis Therapeutics, Inc. is a US subsidiary of Vernalis plc, established to commercialize extended-release formulations of prescription products for the US market. These products are being developed in partnership with New Jersey based Tris Pharma, Inc.

The NDA for the lead product, Tuzistra^® XR (codeine polistirex and chlorpheniramine polistirex) extended-release oral suspension, CIII, was approved by the FDA on 30 April 2015 and the product was launched into the 2015/2016 cough cold season. Click here for full Prescribing Information for Tuzistra^® XR, including Boxed Warning and here for the Medication Guide.

In October 2015, Vernalis also acquired the US rights to Moxatag^®, a once-a-day amoxicillin for strep throat in adult and pediatric patients 12 years of age or older. Click here for full Prescribing Information for Moxatag^®.

Vernalis Therapeutics, Inc. takes its responsibility as a pharmaceutical company seriously promoting and supporting a culture of integrity and compliance.